A Phase 1 interventional study of FB102 and Placebo in Alopecia Areata, sponsored by Forte Biosciences, Inc.. Recruiting at 6 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-20.
Sponsored by Forte Biosciences, Inc. (part of argenx) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Alopecia Areata with a site in Australia — 3 open to participants now, 4 under way, 2 of them phase 3. Alopecia Areata · Australia.
Among the 15 studies in Alopecia Areata with a site in Australia, this one is the 13th largest by planned enrollment, is the only one that started in 2025, is one of 3 in phase 1, and was the 14th registered.
220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.
Browse Alopecia Areata studies →3 of the 15 studies in Alopecia Areata with a site in Australia are open now. Recruiting first, the newest first:
AbbVie · Sites in Australia, United States, Japan and 1 more country
Ages 6–17
AbbVie · Sites in Australia, United States, Argentina and 25 more countries
Ages 12–63
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 5
First in 2016; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 32 is below the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 94 across the 15 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under Forte Biosciences, Inc., one of the names counted as argenx. Under that name alone:
Forte Biosciences, Inc. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
argenx has 1 study filed under Alopecia Areata — fewer than ten, so there is no comparison to draw.
2 of the studies in Alopecia Areata with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07205159Forte Biosciences, Inc.A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata. | 2027-03-10 |
| NCT06602232Dren BioA Study of DR-01 in Subjects With Alopecia Areata and Vitiligo | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Alopecia Areata with a site in Australia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).
Up to approximately 32 participants who meet all the Screening eligibility criteria will be randomized in a 3:1 ratio to receive FB102, or placebo dosing to match.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical diagnosis of severe to very severe AA with ≥50% scalp hair loss (including AT or AU) confirmed by SALT score and central photo review; no other cause of hair loss.
Exclusion Criteria:
Note: There are additional exclusion criteria. The study center will determine if participant meets all of the criteria
Participants will receive FB102.
Drug: FB102
Matching placebo
Drug: Placebo
Route of administration- Intravenous (IV)
Route of administration- Intravenous (IV)
Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Time frame: Upto 36 Weeks post first dose administration
Change from Baseline of Severity of Alopecia Tool (SALT) score at Week 16.
The Severity of Alopecia Tool (SALT) score ranges from 0 (no scalp hair loss) to 100 (complete scalp hair loss), with higher scores indicating greater severity. Change from baseline in SALT score at Week 16 will assess treatment effect. The AA-IGA categorizes SALT scores as follows: 0 = None (0%), 1 = Limited (1-20%), 2 = Moderate (21-49%), 3 = Severe (50-94%), 4 = Very Severe (95-100%).
Time frame: From Screening through Week 16.
Started Oct 2025 (actual). Primary completion is estimated for Mar 2027, 16 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: FB102